DelveInsight’s Pancreatic Endocrine Tumor Market Insights report provides a thorough understanding of current treatment practices, emerging Pancreatic Endocrine Tumor market share of the individual therapies, current and forecasted Pancreatic Endocrine Tumor Market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

 

Pancreatic Endocrine Tumor Overview

Pancreatic neuroendocrine tumors (PNETS) are well-differentiated, low, intermediate, or high-grade neuroendocrine neoplasm, which is composed of cells showing minimal to moderate atypia, displaying organoid patterns, lacking necrosis, and expressing general markers of neuroendocrine differentiation (diffuse and intense synaptophysin and usually also chromogranin A staining) and hormones (usually intense but not necessarily diffuse), either orthotopic or ectopic to the pancreas.

 

Some of the key highlights of the Pancreatic Endocrine Tumor Market Report

• According to DelveInsight’s analysis, metastatic cases of Pancreatic Neuroendocrine Tumors are more prominent in comparison to localized, regionally advanced and unstaged cases.
• According to DelveInsight’s analysis, the total prevalent population of PNET in the 7MM reported to be 8,470 cases in 2019.
• Males are more prone to PNET than females among all countries.
• The total prevalent cases of Non-functional PNET exceeds the Functional PNET with 9:1 ratio respectively.
• In the symptom based prevalence of PNETs, Gastrinoma has reported to be occur in highest cases, followed by Insulinoma, Glucagonoma, VIPoma and Somatostatinoma.
• Pancreatic Endocrine Tumor market companies are included like Advanced Accelerator Applications, Novartis Pharmaceutical, Ipsen Pharma S.A.S., Pfizer, and many others.
• Pancreatic Endocrine Tumor market drugs are included like Lutathera, Afinitor, Somatuline Depot, Sutent, and many others.

 

Pancreatic Endocrine Tumor Types

Functional pancreatic NETs include: Gastrinoma, Insulinoma, Glucagonoma and Other types of tumors (VIPomas, which make vasoactive intestinal peptide. VIPoma may also be called Verner-Morrison syndrome, Somatostatinomas, which make somatostatin).

  

Pancreatic Endocrine Tumor Diagnosis

In the last decades, the incidental diagnosis of neoplasms has been greatly increased due to the widespread use of advanced imaging techniques. Indeed, the diagnosis of pancreatic neuroendocrine tumors has increased fourfold to sevenfold. Furthermore, the size of these lesions at diagnosis has considerably decreased, and the detection of tumors < 2 cm ranges from 26% to 61%.

 

Pancreatic Endocrine Tumor Treatment

The treatment landscape of PNET comprises of surgical as well as pharmacotherapies. Although surgical therapies occupy the major share to date and are mainly from the first line of defense, but a large section of the patient population present with advanced disease and are not candidates for resection. In such cases, therapeutic modalities come into play which are primarily symptomatic in nature.

 

Download Free Sample Report Now @ Pancreatic Endocrine Tumor Treatment Market

 

List of the Pancreatic Endocrine Tumor Market Companies includes-

• Advanced Accelerator Applications
• Novartis Pharmaceutical
• Ipsen Pharma S.A.S.
• Pfizer
• And many others

 

List of the Pancreatic Endocrine Tumor Drugs includes-

• Lutathera
• Afinitor
• Somatuline Depot
• Sutent
• And many others

 

Pancreatic Endocrine Tumor Market Drivers

• Advancement in technology
• Exome sequencing
• Increased Focus on Prophylactic Treatment

 

Pancreatic Endocrine Tumor Market Barriers

• Shortage of in vitro and animal models to study disease pathogenesis and treatment
• No uniform pathological classification or staging system
• Paucity of specific targets for new therapies

 

Pancreatic Endocrine Tumor Market Report Scope

• The report covers the descriptive overview of Pancreatic Endocrine Tumor, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Pancreatic Endocrine Tumor epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Pancreatic Endocrine Tumor is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Pancreatic Endocrine Tumor market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Pancreatic Endocrine Tumor market.

 

Get detailed information about therapies @ Pancreatic Endocrine Tumor Therapies

 

Table of content

1. Key Insights
2. Executive Summary
3. Competitive Intelligence Analysis
4. Market Overview at a Glance
5. Disease Background and Overview
6. Patient Journey
7. Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Pancreatic Endocrine Tumor Treatment
11. Marketed Products
12. Emerging Therapies
13. Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/